Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mumps vaccine, live + influenza vaccine, inactivated, quadrivalent
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This combination regimen consists of a live-attenuated mumps vaccine and a quadrivalent inactivated influenza vaccine (QIV). It is primarily developed and evaluated by Sinovac Biotech (specifically Sinovac Dalian Vaccine Technology) for the prevention of mumps and seasonal influenza in school-aged populations. The mumps component is a live-attenuated virus vaccine designed to induce protective antibodies against the mumps virus, while the quadrivalent influenza component contains inactivated viral antigens from four strains (typically two Influenza A subtypes and two Influenza B lineages) to provide broad protection against seasonal flu. Clinical evaluation, including Phase 4 trials, has focused on the safety and immunogenicity of booster doses when these vaccines are administered concomitantly to improve vaccination efficiency and compliance.
- Other names
- mumps vaccine, live and quadrivalent inactivated influenza vaccineconcomitant mumps and quadrivalent influenza vaccinationmumps vaccine, live + influenza vaccine, inactivated, quadrivalent (Sinovac)
Beyond the preview
Go deeper on mumps vaccine, live + influenza vaccine, inactivated, quadrivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mumps vaccine, live + influenza vaccine, inactivated, quadrivalent.